NCT03960268 is a EARLY_PHASE1 clinical trial of Brodalumab in Hidradenitis Suppurativa, sponsored by Rockefeller University.

Who is sponsoring NCT03960268?

NCT03960268 is sponsored by Rockefeller University.

What drugs are being tested in NCT03960268?

Interventions in NCT03960268: Brodalumab.

What condition does NCT03960268 study?

NCT03960268 studies Hidradenitis Suppurativa.

Is NCT03960268 still recruiting?

NCT03960268 is currently completed. Last updated 4 June 2020.

Last reviewed 2020-06-04 · How we verify

NCT03960268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Completed EARLY_PHASE1 Last updated 4 June 2020

What this trial tests

EARLY_PHASE1 trial testing Brodalumab in Hidradenitis Suppurativa in 10 participants. Completed in 1 June 2020.

Timeline

28 May 2019

Primary endpoint
1 June 2020

1 June 2020

Quick facts

Lead sponsor	Rockefeller University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	28 May 2019
Primary completion	1 June 2020
Estimated completion	1 June 2020
Sites	1 location across United States

Drugs / interventions tested

Brodalumab (BRODALUMAB) — full drug profile →

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Rockefeller University

Who can join

Adults 18 to 99, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.
Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, et al · · 2021 · cited 103× · PMID 33548397 · DOI 10.1016/j.jaci.2020.12.651
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
Frew JW, Navrazhina K, Grand D, Sullivan-Whalen M, et al · · 2020 · cited 81× · PMID 32416208 · DOI 10.1016/j.jaad.2020.05.007
Single-cell transcriptomics suggest distinct upstream drivers of IL-17A/F in hidradenitis versus psoriasis.
Kim J, Lee J, Li X, Lee HS, et al · · 2023 · cited 62× · PMID 37271319 · DOI 10.1016/j.jaci.2023.05.012
Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.
Del Duca E, Morelli P, Bennardo L, Di Raimondo C, et al · · 2020 · cited 52× · PMID 33182701 · DOI 10.3390/ijms21228436
Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
Navrazhina K, Frew JW, Grand D, Williams SC, et al · · 2022 · cited 43× · PMID 35191018 · DOI 10.1111/bjd.21060
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.
Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, et al · · 2023 · cited 19× · PMID 37896210 · DOI 10.3390/pharmaceutics15102450
Rapid resolution of pyoderma gangrenosum with brodalumab therapy.
Tee MW, Avarbock AB, Ungar J, Frew JW. · · 2020 · cited 17× · PMID 32953958 · DOI 10.1016/j.jdcr.2020.08.033
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.
Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. · · 2025 · cited 8× · PMID 39604776 · DOI 10.1007/s40259-024-00687-w

Verify or expand the search:

Other trials of Brodalumab

Trials testing the same drug.

NCT04305327 — Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis · Phase 3 · terminated
NCT04306315 — Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and · Phase 4 · completed
NCT05132231 — Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Wor · active not recruiting
NCT04979520 — Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa · EARLY_PHASE1 · completed
NCT04533737 — Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Respons · Phase 4 · terminated

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other Rockefeller University trials

Trials by the same sponsor.

NCT06887543 — The Impact of Time Restricted Eating on Type 2 Diabetes · NA · terminated
NCT06424132 — Thermogenic Silencer Regulatory Factors in Humans · NA · active not recruiting
NCT06223035 — Myokine Identification Following Acute Exercise · NA · completed
NCT06146218 — Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress · NA · completed
NCT05856890 — HepB mAb19 in Individuals With Chronic Hepatitis B Infection · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03960268 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rockefeller University
Last refreshed: 4 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03960268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing